An uneven smile after Botox: what to document and ask
An uneven smile after cosmetic botulinum toxin deserves an assessment of timing, expression, injection sites and other symptoms. Lower-face smile correction is not a BOTOX Cosmetic approved indication, and an online “balancing” injection recipe cannot establish the cause or safe response.
An uneven smile noticed after Botox Cosmetic should be assessed by the treating clinician with the injection record, the timing of the change, rest and smiling views, and any functional symptoms. The product’s FDA-approved cosmetic indications include specified upper-face lines and platysma bands, not smile correction. A new smile change may involve local muscle effect, ordinary pre-existing asymmetry or another cause; a photo cannot identify which. Do not use an online injection diagram as a correction plan.12
The practical problem is not that every smile must be perfectly symmetric. It is that a person expected one cosmetic change and notices a different movement. A useful response preserves evidence of the baseline and the treatment rather than treating a snapshot as a diagnosis.
Describe the motion before naming the cause
An asymmetry may be visible only while smiling, only at rest, while speaking, or while eating and drinking. It may involve one mouth corner, the upper lip or a broader facial expression. Those observations are not interchangeable. Note when the change first appeared, whether it is stable or evolving, and what other symptoms accompany it.
| Observation | Useful record for the clinician | Why a photo alone is limited |
|---|---|---|
| Smile differs side to side | Matched rest and natural-smile views before and after treatment | Angle, expression and lighting can exaggerate asymmetry |
| Drinking or chewing feels different | A clear description of the function affected and onset | Movement or weakness needs direct assessment |
| Drooping brow or eyelid | Which area actually moved and whether vision is affected | The cause and response differ from mouth movement |
| Speech, swallowing or breathing difficulty, generalized weakness | Seek immediate medical attention | The label's distant-spread warning is not a cosmetic follow-up issue |
BOTOX Cosmetic labeling describes local weakness as an expected pharmacologic action in an injected muscle and warns that effects can spread. Its warning says to seek immediate medical attention if speech, swallowing or breathing difficulties occur. The table distinguishes a local cosmetic concern from symptoms requiring urgent assessment; it is not a way to diagnose either from home.1
The eyelid and brow guide covers a different post-treatment observation. A mouth-corner change should not be solved by advice written for a drooping eyelid.
Get the actual treatment map
Ask the treating practice for the product name, treatment date, recorded sites, clinical rationale, and follow-up note. The FDA label says the units of BOTOX Cosmetic are product-specific and cannot be converted casually to another botulinum toxin product. A correction proposal based only on “how many units” without the formulation and site record is incomplete.1
The product label approves temporary improvement in moderate-to-severe glabellar, lateral canthal and forehead lines and platysma bands under its specific conditions. It does not list “fix an uneven smile” as an approved cosmetic indication. Lower-face uses may occur in clinical practice, but a clinic should call the use off-label rather than calling the entire named product unapproved.1
A retrospective single-center study reported full-face treatment that included several lower-face targets. It shows that such placements have been studied, not that any one additional injection is the standard remedy for a new asymmetry. Its observational design and treatment mix cannot establish the safest response for a person whose injection map and baseline are unknown.2
Avoid a second treatment before the first is understood
Social posts often propose “add one unit on the other side” or name a particular mouth muscle. That advice assumes the first effect, the muscle involved, timing, product and cause. A clinician may decide observation, reassessment or another approach is appropriate, but this article cannot supply an injection site, amount or timeline.
The issue can also be unrelated to the cosmetic treatment. New neurological symptoms, facial pain or other functional changes should not be filed away as a beauty complication merely because they appeared after a visit. Tell the clinician exactly what changed and seek appropriate care for concerning symptoms.
When the treating practice explains the plan, ask it to separate expected temporary local effects from a suspected adverse event and from a different diagnosis. A good explanation includes what evidence supports its assessment, who is responsible for follow-up, and how the plan changes if function is affected.
Compare provider response, not just injection price
Before any future cosmetic toxin visit, ask how the practice documents baseline symmetry, product and injection map, how it handles unexpected movement, and which clinician is available for follow-up. The Botox provider lane helps discover local options, while those questions reveal the quality of the consultation and response process.
If the original goal was a downturned mouth corner, the DAO article explains that planned off-label decision. It is not a rescue protocol for an unexpected uneven smile. The next step for a new change is to contact the treating clinician with the dated record and describe both appearance and function, so the assessment is about the actual person and product rather than a guessed muscle diagram.
Sources
- U.S. Food and Drug Administration. BOTOX Cosmetic prescribing information, revised October 2024. Lists approved cosmetic sites and boxed distant-spread warning, product-specific unit non-equivalence and local weakness; smile correction is not a listed indication. Accessed .
- PubMed / Journal of Cosmetic Dermatology. Full-face onabotulinumtoxinA single-center retrospective study. Documents that off-label lower-face and neck uses have been studied in a limited observational setting; it does not validate a consumer correction technique or event rate. Accessed .